Primer Podcast #13 - Palantir Leak, Lambda School Disruption, Convalescent Plasma and our Investing Process

In this episode we are talking about the new covid-19 convalescent plasma therapy that got emergency authorization as part of the Trump Administration’s “Operation Warp Speed” program. The trials that they are using to prove the efficacy of the process has seen mortality decreases of 35%. The recent authorization has also seen backlash from Fauci, saying that the data is too weak to promote it. Futures at the time of writing this are around .3% positive. We also talked about Lambda school and their series C raising 74M. This will allow them to operate more efficiency by allowing them to take on more students. Lambda School is a 18 month course that allows users to learn programming and get a job that pays a salary of at least $50k where students do not pay the tuition until they land a job above $50k. We also discussed some leaked information that was discussed in a TechCrunch article around Palantir’s financials. They had revenue of over 700M a growth of 25% from the previous year (2018), but their losses are 500M leaving a -78% profit margin. The company is over 10 years old with 125 total customers bringing in an average of 7.4M per employee. The company should be releasing their real S-1 soon and we will bring you the information about that. We also talked about Osmind, which is a software for mental health providers and their patients. Their software and data insights improve clinical care while advancing research towards new treatments and precision health. We finally talked about our final topic in regards to how we see the market and how we are investing. 

Be sure to follow us on our Instagram @Primerpodcasting and follow us on Linkedin, why not?

-Connor & Luca